Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PARP inhibitor olaparib enhances the efficacy of radiotherapy on XRCC2-deficient colorectal cancer cells

28 May 2022

Abstract excerpt

The use of PARP inhibitors in combination with radiotherapy is a promising strategy to locally enhance DNA damage in tumors. Loss of XRCC2 compromises DNA damage repairs, and induced DNA damage burdens may increase the reliance on PARP-dependent DNA repairs of cancer cells to render cell susceptibility to PARP inhibitor therapy. Here we tested the hypothesis that XRCC2 loss sensitizes colorectal cancer (CRC) to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell death mechanisms and regulation
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35643812
DOI: 10.1038/s41419-022-04967-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PARP inhibitor olaparib enhances the efficacy of radiotherapy on XRCC2-deficient colorectal cancer cellsPMID 35643812Read ↗

Targeting PARP-1 and DNA Damage Response Defects in Colorectal Cancer Chemotherapy with Established and Novel PARP InhibitorsSemantic proximity Read ↗

A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin.Semantic proximity Read ↗

Olaparib combined with CDK12-IN-3 to promote genomic instability and cell death in ovarian cancerSemantic proximity Read ↗

PARPi Decreased Primary Ovarian Cancer Organoid Growth Through Early Apoptosis and Base Excision Repair PathwaySemantic proximity Read ↗

PARP in colorectal cancer: Molecular mechanisms, immunity, clinical trials, and drug combinationsSemantic proximity Read ↗

Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell linesSemantic proximity Read ↗

Olaparib-Induced Senescence Is Bypassed through G2–M Checkpoint Override in Olaparib-Resistant Prostate CancerSemantic proximity Read ↗

Targeting the DNA Damage Response and DNA Repair Pathways to Enhance Radiosensitivity in Colorectal CancerSemantic proximity Read ↗

Combinatorial Efficacy of Olaparib with Radiation and ATR Inhibitor Requires PARP1 Protein in Homologous Recombination–Proficient Pancreatic CancerSemantic proximity Read ↗

Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal CancerSemantic proximity Read ↗

The combination of olaparib and camptothecin for effective radiosensitizationSemantic proximity Read ↗

ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor OlaparibSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.